BENZACLIN
LOE ApproachingNDATOPICALGEL
Approved
Dec 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
BENZACLIN by Bausch + Lomb is clinical pharmacology an in vitro percutaneous penetration study comparing benzaclin topical gel and topical 1% clindamycin gel alone, demonstrated there was no statistical difference in penetration between the two drugs. First approved in 2000.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BENZACLIN is a topical gel combination product containing clindamycin and benzoyl peroxide approved in 2000 for acne vulgaris treatment. It works through dual mechanism: clindamycin provides antimicrobial activity against Propionibacterium acnes, while benzoyl peroxide concentrates in sebaceous follicles with peroxide and oxidizing properties. The combination is applied topically with minimal systemic absorption (clindamycin <1%, benzoyl peroxide <2%).
LOE Approaching
Product faces LOE risk with moderate competitive pressure (30/100), indicating potential team downsizing or transition to generic support roles.
Mechanism of Action
CLINICAL PHARMACOLOGY An in vitro percutaneous penetration study comparing BenzaClin Topical Gel and topical 1% clindamycin gel alone, demonstrated there was no statistical difference in penetration between the two drugs. Mean systemic bioavailability of topical clindamycin in BenzaClin Topical Gel…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings signal minimal active hiring; career opportunity limited to existing team transitions or backfill roles. Working on BENZACLIN at LOE-approaching stage offers experience in defensive marketing, generic transition management, and niche dermatology positioning.
Worked on BENZACLIN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.